Non-automatic Control of Gait and Posture in Obstructive Sleep Apnea Syndrome (CIH-Gait)
NCT02345694, Not applicable, Completed, University Hospital, Grenoble
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Non-automatic Control of Gait and Posture in Obstructive Sleep Apnea Syndrome (CIH-Gait) | ClinicalTrials.gov |
| NCT number | NCT02345694 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 24 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University Hospital, Grenoble | ClinicalTrials.gov |
| Conditions | Obstructive Sleep Apnea Syndrome | ClinicalTrials.gov |
| Interventions | Effective CPAP, Sub-therapeutic CPAP | ClinicalTrials.gov |
| First posted | 2015-01-26 | ClinicalTrials.gov |
| Last updated | 2020-03-18 | ClinicalTrials.gov |
Registered outcomes 14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from baseline of stride time coefficient of variation at 8 weeks | Baseline and 8 weeks | The stride time will be recorded during an overground walking test, under single (walking alone) and dual-task (walking while performing a cognitive task) condition. The cognitive task used in our protocol is an electronic Stroop test, displayed on a screen at the end of the 10 meters walkway. The coefficient of variation allows us to estimate stride time variability, known to be the reflect of gait control efficiency when it exhibits low values. | ClinicalTrials.gov |
| Secondary | Change from baseline of single support time and percentage at 8 weeks | Baseline and 8 weeks | To assess gait stability, mean single support time will be assess under single (walking alone) and dual task condition (walking while performing a cognitive task) and its coefficient of variation calculate. | ClinicalTrials.gov |
| Secondary | Change from baseline of double support time and percentage at 8 weeks | Baseline and 8 weeks | To assess gait stability, mean double support time will be assess and its coefficient of variation calculate. | ClinicalTrials.gov |
| Secondary | Change from baseline of gait speed at 8 weeks | Baseline and 8 weeks | ClinicalTrials.gov | |
| Secondary | Change from baseline of step length at 8 weeks | Baseline and 8 weeks | ClinicalTrials.gov | |
| Secondary | Change from baseline of step width at 8 weeks | Baseline and 8 weeks | ClinicalTrials.gov | |
| Secondary | Change from baseline of the center-of-pressure area at 8 weeks | Baseline and 8 weeks | Studying gait implies posture assessment as the link between gait stability and an efficient postural control is tenuous. | ClinicalTrials.gov |
| Secondary | Change from baseline of the center-of-pressure length at 8 weeks | Baseline and 8 weeks | Combined with center-of-pressure (CoP) area, the length (path of CoP) of CoP permits efficient measurement of CoP spatial variability. | ClinicalTrials.gov |
| Secondary | Change from baseline of the center-of-pressure mean speed at 8 weeks | Baseline and 8 weeks | The mean speed represents a good index of the amount of neuromuscular activity required to regulate postural control. | ClinicalTrials.gov |
| Secondary | Change from baseline of oxy-haemoglobin concentration of bilateral prefrontal cortices at 8 weeks | Baseline and 8 weeks | The oxyhaemoglobin concentration will be recorded during an treadmill walking test, under single (walking alone) and dual-task (walking while performing a cognitive task) condition. The cognitive task used in our protocol is an electronic Stroop test, displayed on a screen placed in front of the patient. We use a fNIRS (Near Infrared Spectroscopy) device, disposed bilaterally opposite to prefrontal cortices to assess the change of oxyhemoglobin concentration over different motor and cognitive tasks. | ClinicalTrials.gov |
| Secondary | Change from baseline of deoxy-haemoglobin concentration of bilateral prefrontal cortices at 8 weeks | Baseline and 8 weeks | The deoxyhemoglobin concentration will be recorded as oxyhaemoglobin concentration. | ClinicalTrials.gov |
| Secondary | Change from baseline of total haemoglobin concentration of bilateral prefrontal cortices at 8 weeks | Baseline and 8 weeks | The total haemoglobin concentration will be recorded as oxyhaemoglobin concentration. | ClinicalTrials.gov |
| Other | Change from baseline in Dual Task Cost (DTC) at 8 weeks | Baseline and 8 weeks | Dual Task Cost = \[(Dual Task % correct - Single Task % correct) x 100 / Single Task % correct\] | ClinicalTrials.gov |
| Other | Continuous Positive Airway Pressure Observance at 8 weeks | 8 weeks | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 3
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)